New oral painkiller KHN702 enters human testing for Post-Op pain
NCT ID NCT07277933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new oral drug called KHN702 for moderate to severe pain after surgery. About 24 adults will receive either the drug or a placebo to see if it is safe and helps reduce pain. The study is double-blind, meaning neither patients nor doctors know who gets the real drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KHN702 tablet
- What this could lead to
- If it works, this could lead to a new oral painkiller for post-surgery pain.
- What could go wrong
- This is a very early Phase 1 trial with only 24 people. It is designed mainly to check safety, not prove effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTOPERATIVE PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can patients safely dispense their own pain medicine after surgery?
- Can a VR headset calm nerves before surgery?
- Can a less invasive nerve block match the gold standard for chest surgery pain?
- Could a Pre-Surgery nerve block speed up recovery after hip fracture?
- One injection or many? a test to ease breast surgery pain
- One injection vs. two: a new approach to shoulder surgery pain?